DUBLIN – Xtrackers (IE) plc announced today that it will hold an extraordinary general meeting on May 15, 2026, to vote on changing the investment objective of its MSCI Genomic Healthcare Innovation UCITS ETF, according to a press release statement.
The fund currently tracks the MSCI ACWI IMI Genomic Innovation Select Screened 100 Index, which includes companies with high exposure to genomic healthcare sector activities and applies environmental, social and governance criteria. The proposed change would shift the fund to track the MSCI World Biotechnology 20/35 Index, which represents large and medium capitalization companies in developed global markets classified within the Biotechnology Industry according to the Global Industry Classification Standard.
The new reference index does not apply ESG screens. Following the proposed changes, the fund will no longer promote environmental or social characteristics and will be subject to disclosure requirements under Article 6 of the Sustainable Finance Disclosure Regulation, rather than Article 8.
If shareholders approve the resolution, the fund’s name will change to Xtrackers MSCI World Biotechnology UCITS ETF. The management company fee for the 1C share class (ISIN:IE000KD0BZ68) will decrease from 0.15% per annum to 0.10% per annum, reducing the all-in fee from 0.30% to 0.25% per annum.
The extraordinary general meeting will take place at 10:00 a.m. Dublin time at 25 North Wall Quay, Dublin 1, Ireland. The resolution requires approval by more than 50% of votes cast. If passed, the changes are expected to take effect on or around June 1, 2026.
Both the current and proposed reference indices are administered by MSCI Limited.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.